|
|
|
|
Gain valuable insights from industry experts on overcoming the unique chemical, technical, and regulatory challenges of AOC development by watching the recorded webinar.
|
|
|
|
|
The development and manufacturability of antibody-oligonucleotide conjugates (AOCs) hinges on understanding and overcoming intricate chemistry and analytical challenges. This article explores the challenges these promising candidates face and how they must be addressed to create a functional and stable conjugate.
|
|
|
|
|
Ready to kick-start your bioconjugate R&D program? In this piece, learn from real-world case studies that demonstrate how to accelerate the development of complex bioconjugates and unlock new possibilities for targeted therapies. These de-risking strategies can help you in advancing the next generation of precision medicine.
|
|
|
|
|
Explore how this comprehensive, multi-step assay approach — combining real-time apoptosis tracking, secondary necrosis detection, and optimized viability measurements — can significantly improve the precision, sensitivity, and reliability of your ADC potency assessments.
|
|
|
|
|
In this on-demand webinar, hear from bioconjugation experts as they review case studies that explore the complexities of oligonucleotide design, GMP standards for ADCs, and how developability can play a significant role in selecting ADC leads with high potential.
|
|
|
|
|
Learn how advanced site-specific conjugation technologies are improving the outcomes of the next generation of ADCs, AOCs, and RDCs with enhanced stability, homogeneous DAR, and streamlined development.
|
|
|
|
|
ThioBridge™ site-specific conjugation technology has the ability to support a number of different conjugation modalities, including bispecific ADCs, dual-payload ADCs, AOCs and RDCs. This case study demonstrates the versatility in the reagent architecture, which allows for variation around DAR, payload, and side chain.
|
|
|
|
|
|
|
